SYSTEMIC LUPUS ERYTHEMATOSUS

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and destroy faulty immune cells in people with severe lupus or scleroderma. The goal is to control the disease by resetting the immune system. The trial involves 18 adults whose …

This study tests a new injectable drug, anifrolumab, for adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding anifrolumab can better control lupus activity and reduce flare-ups. About 367 participan…

This early-stage study is testing a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty B cells. The goal is to see if it is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjögren's…

This study was designed to test a drug called telitacicept for people with moderate-to-severe systemic lupus erythematosus (SLE), an autoimmune disease. The goal was to see if the drug could reduce lupus symptoms and allow lower steroid use. However, the trial was withdrawn befor…

This study tests a daily pill called deucravacitinib against a placebo in 513 people with active moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can reduce lupus disease activity better than a dummy pill. Participants must have had lupus for …

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to see how the drug behaves in the body and if it is safe when used with standard treatments. About 25 children will take part, and the study lasts 68 weeks.

This study tests an experimental drug called MIL62 in 120 adults with active lupus. The goal is to see if it can reduce disease activity better than a placebo. Participants must have moderate to severe lupus and be on a stable treatment plan.

This early-stage study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and destroy fa…

This study planned to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before any partici…

This study tests an experimental drug called obinutuzumab in 303 people with active lupus. The drug targets immune cells to reduce disease flares. Participants receive either the drug or a placebo, plus their usual treatments. The main goal is to see if more people achieve a sign…

This early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in 6 adults, while also seeing if it reduces lupus sympto…

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. The goal is to see if the treatment reduces di…

This study tests whether adding sirolimus to standard lupus therapy helps control active disease better than a placebo. It involves 146 adults with lupus who still have symptoms despite usual care. The main goal is to see if more people achieve a meaningful reduction in disease a…

This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. About 21 adults will receive the therapy to see if it is safe and helps control the disease. The goal is to reduce lupus activity, but ongoing management may stil…

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and attack faul…

This study tests a new medicine called ianalumab, given as a monthly shot, for people with active systemic lupus erythematosus (SLE). The goal is to see if adding ianalumab to standard treatments can better control lupus symptoms and reduce flares. About 288 participants aged 12 …

This early-phase study tests a new treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing severe lupus or scleroderma. About 48 adults with these hard-to-treat autoimmune diseases will receive the therapy to see if it is…

This study tests whether a daily oral medication called deucravacitinib can safely control active moderate-to-severe systemic lupus erythematosus (SLE) better than a placebo. About 516 adults with lupus will take either the drug or a dummy pill for several months. The main goal i…

This study looks back at medical records of 180 adults with systemic lupus erythematosus (SLE) to compare two drugs: telitacicept and belimumab. The goal is to see which one works better at controlling lupus symptoms and has fewer side effects. Participants were already taking on…

This early-stage study tests whether a special type of immune cell, called CAR-T, can safely treat people with severe lupus that hasn't improved with standard treatments. The therapy targets a protein called CD19 on immune cells to calm the overactive immune system. The main goal…

This study tests an oral medication called GLPG3667 for people with active systemic lupus erythematosus (SLE). About 186 adults take the drug or a placebo once daily for 48 weeks. The goal is to see if the drug reduces lupus disease activity safely.

This study watches 551 lupus patients who are starting anifrolumab for the first time as part of their normal care. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to understand the real-world…

This early-phase study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to standard therapies. SC291 uses specially engineered immune cells from a donor to target and destroy faulty B cells driving the disease. The main goal is t…

This study looks at the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). About 760 adults who completed a previous related study will receive the drug and be monitored for side effects. The goal is to see if the drug is s…

This study compares a new 2mL auto-injector or pre-filled syringe to the standard two 1mL injections of ianalumab in 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus. The goal is to see if the new device delivers the same amount of medicine safely. Participants w…

This study tests whether a new drug called ianalumab, given as a monthly or quarterly shot alongside standard lupus treatments, can better control active lupus than standard care alone. About 436 people with lupus will take part. The goal is to see if the drug reduces disease act…

This study tests a non-invasive device that uses low-frequency electromagnetic waves to help immune cells communicate better. The goal is to reduce flare-ups in people with lupus, rheumatoid arthritis, or multiple sclerosis. 120 adults will receive either real or placebo sessions…

This study looks at the long-term safety of enpatoran, an oral medication, in people with lupus who have already finished a 24-week treatment in a previous study. About 379 participants will take different doses of the drug and be monitored for side effects. The goal is to see if…

This study tests an experimental drug called SAR441344 in people with active systemic lupus erythematosus (SLE). The goal is to see if it can reduce lupus symptoms and disease activity better than a placebo. About 109 adults aged 18 to 70 will receive either the drug or a placebo…

This study looks at how safe and effective the Shingrix vaccine is for people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. About 2,000 participants will receive the vaccine or a placebo to check for disease flares an…

This study tests whether lisinopril, a blood pressure drug that works in the brain, can improve memory and concentration problems in people with lupus. About 36 adults with lupus will take either lisinopril or another similar drug for 12 months. Researchers will measure changes i…

This study tests a program called HOP-STEP that helps doctors better discuss pregnancy prevention and planning with women who have lupus. The program was already successful at one hospital, and now researchers are adapting it for use at other centers. The goal is to see if it imp…

This study looks at 500 adults with lupus to see if certain immune system markers can better predict who is at high risk for heart disease. Researchers will track changes in artery health over time using ultrasound. The goal is to improve heart risk assessment beyond traditional …

This study is the first time a new drug, GSK4347859, is being tested in humans. The goal is to see if it is safe and how the body processes it. It involves 65 healthy volunteers and is currently on hold. The drug is being developed for lupus, an autoimmune disease.

This study was designed to track pregnancies in women with rare autoimmune diseases like lupus, arthritis, and scleroderma. The goal was to learn about complications and improve care. However, the study was withdrawn before enrolling any participants, so no results are available.